TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07422480: A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syn

Sponsor: Takeda · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT07422480 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07422480 Rescue Dossier →